EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment of Fabry Disease: Established and Emerging Therapies

Muhammad Umer, Dinesh K Kalra iD

Pharmaceuticals · 20.02.2023 · 16 (2) · 320

DOI: 10.3390/ph16020320 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 20.02.2023. Verfasst von Muhammad Umer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Louisville, Louisville, KY 40202, USA. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fabry disease (FD) is a rare, X-linked inherited disorder of glycosphingolipid metabolism. It leads to the progressive accumulation of globotriaosylceramide within lysosomes due to a deficiency of α-galactosidase A enzyme. It involves multiple organs, predominantly the renal, cardiac, and cerebrovascular systems. Early diagnosis and treatment are critical to prevent progression to irreversible tissue damage and organ failure, and to halt life-threatening complications that can significantly reduce life expectancy. This review will focus on the established and emerging treatment options for FD.

Schlagwörter

Stichwörter der Autor:innen

Fabry diseasechaperone therapyenzyme replacement therapygene therapyleft ventricular hypertrophy

Autor:innen und Institutionen

  • Division of Cardiology, University of Louisville, Louisville, KY 40202, USA.

ORCID-Profile: Dinesh K Kalra

Zitieren

APA

Umer, M., & Kalra, D. K. (2023). Treatment of Fabry Disease: Established and Emerging Therapies. Pharmaceuticals, 16(2), 320. https://doi.org/10.3390/ph16020320

Vancouver

Umer M, Kalra DK. Treatment of Fabry Disease: Established and Emerging Therapies. Pharmaceuticals. 2023;16(2):320. doi:10.3390/ph16020320

BibTeX
@article{Umer2023,
  author = {Umer, Muhammad and Kalra, Dinesh K},
  title = {Treatment of Fabry Disease: Established and Emerging Therapies},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {2},
  pages = {320},
  doi = {10.3390/ph16020320}
}
Kostenlos starten →